CTLT Stock: Catalent, Inc. Stock Price, Analysis & Insights
Get live ctlt stock price $63.48, comprehensive Catalent, Inc. stock analysis, charts, news, and expert forecast. Real-time ctlt stock data and investment insights.
Loading chart...
Company Overview
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Company Information
- CEO
- Alessandro Maselli
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 17000
Contact Information
- Website
- https://www.catalent.com
- Address
- 14 Schoolhouse Road
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Catalent, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Alessandro Maselli, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - Specialty & Generic model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Catalent, Inc. competes in the Drug Manufacturers - Specialty & Generic within the broader Healthcare. With 11.5 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, Catalent, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Catalent, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Catalent, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Catalent, Inc.
- ⚠Investors should consider how Catalent, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
11.52B
P/E Ratio
-27.84
Beta
1.16
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 11.52B market capitalization
- Trading Volume: 13.67M shares traded today
- Price Range: 52-week range of $42.11 - $63.50
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for Catalent, Inc.
Catalent, Inc. (CTLT) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. With a current market capitalization of 11.52B, the company represents a significant player in its market. The stock is currently trading at $63.48 with a positivedaily change of 0.00%.
The company's 17000 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -27.84, beta of 1.16, and 52-week price range from $42.11 to $63.50when evaluating investment opportunities.
Why Invest in Catalent, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under Alessandro Maselli
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.